A complete 4<scp>DCT</scp>‐ventilation functional avoidance virtual trial: Developing strategies for prospective clinical trials

Abstract

Our work demonstrated that 60-70% of stage III patients would be eligible for functional planning and that a typical functional lung mean dose reduction of 2.8 Gy can be expected relative to standard clinical plans. These findings provide salient data for the development of functional clinical trials.